Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
Apr 25 REGN AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Apr 25 REGN Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
Apr 25 REGN Regeneron (REGN) Reports Next Week: What You Should Expect
Apr 25 REGN UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Apr 25 REGN The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Apr 25 REGN Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
Apr 25 MGTX MeiraGTx Holdings plc (NASDAQ:MGTX): Is Breakeven Near?
Apr 25 REGN Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Apr 25 REGN Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Apr 25 REGN Regeneron expands in gene editing with Mammoth deal
Apr 24 REGN Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Apr 24 REGN Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Apr 23 EYPT Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Apr 22 REGN Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Apr 22 REGN Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags